Enveric Biosciences Reports Positive Preclinical Study Results for EB-003

• Enveric Biosciences reported positive results from IND-enabling laboratory studies of EB-003, its lead non-hallucinogenic neuroplastogenic drug candidate.
• Screening across more than 70 assays indicated favorable intestinal absorption potential, metabolic stability and low potential for drug interactions.
• Results support continued development toward a planned first-in-human clinical trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261021565311) on October 21, 2026, and is solely responsible for the information contained therein.